Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lineage Cell Therapeutics (LCTX) Depreciation & Amortization (CF): 2010-2025

Historic Depreciation & Amortization (CF) for Lineage Cell Therapeutics (LCTX) over the last 15 years, with Sep 2025 value amounting to $178,000.

  • Lineage Cell Therapeutics' Depreciation & Amortization (CF) rose 26.24% to $178,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $664,000, marking a year-over-year increase of 14.68%. This contributed to the annual value of $587,000 for FY2024, which is 4.45% up from last year.
  • Per Lineage Cell Therapeutics' latest filing, its Depreciation & Amortization (CF) stood at $178,000 for Q3 2025, which was up 4.09% from $171,000 recorded in Q2 2025.
  • Lineage Cell Therapeutics' Depreciation & Amortization (CF)'s 5-year high stood at $178,000 during Q3 2025, with a 5-year trough of $138,000 in Q1 2023.
  • Its 3-year average for Depreciation & Amortization (CF) is $151,091, with a median of $143,000 in 2023.
  • Its Depreciation & Amortization (CF) has fluctuated over the past 5 years, first decreased by 21.90% in 2021, then climbed by 26.24% in 2025.
  • Quarterly analysis of 5 years shows Lineage Cell Therapeutics' Depreciation & Amortization (CF) stood at $159,000 in 2021, then dropped by 11.32% to $141,000 in 2022, then increased by 1.42% to $143,000 in 2023, then grew by 5.59% to $151,000 in 2024, then rose by 26.24% to $178,000 in 2025.
  • Its Depreciation & Amortization (CF) stands at $178,000 for Q3 2025, versus $171,000 for Q2 2025 and $164,000 for Q1 2025.